Julian Upton

Biopharma experts at the forefront of applying real-world data and real-world evidence across the product life cycle converge to discuss the lingering challenges in fully realizing the vast potential of these insights to transform the value equation.

With more promising products emerging, investment risks remain.

After helping lead Novo Nordisk on a transformational journey from a troubled 2016 to double-digit growth in 2021, Doug Langa, Executive Vice President, Head of North America Operations and President of Novo Nordisk, Inc., is calling on his experience of taking the less conventional and sometimes unexpected routes to success to lead Novo Nordisk into new territory.

A new report examining pharma sector exposure makes for sobering reading, especially in US.

Illinois BIO‘s (iBIO) new chairperson, Horizon Therapeutic‘s Marilyn Vetter, outlines the work she plans to do to expand the state’s existing life sciences ecosystem.

Spurred on by COVID-19 and companies’ evolving digital maturity, AI looks set to gain a real foothold in pharma’s promotional activities.